Growth Metrics

Takeda Pharmaceutical (TAK) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $203.2 million.

  • Takeda Pharmaceutical's Non-Current Deferred Tax Liability fell 1797.97% to $203.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $203.2 million, marking a year-over-year decrease of 1797.97%. This contributed to the annual value of $230.8 million for FY2025, which is 7074.9% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Non-Current Deferred Tax Liability of $203.2 million as of Q4 2025, which was down 1797.97% from $224.2 million recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Non-Current Deferred Tax Liability ranged from a high of $5.1 billion in Q1 2021 and a low of $203.2 million during Q4 2025
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $1.8 billion (2023), whereas its average is $2.1 billion.
  • In the last 5 years, Takeda Pharmaceutical's Non-Current Deferred Tax Liability tumbled by 1084.57% in 2021 and then crashed by 8187.02% in 2024.
  • Takeda Pharmaceutical's Non-Current Deferred Tax Liability (Quarter) stood at $4.9 billion in 2021, then crashed by 44.02% to $2.8 billion in 2022, then tumbled by 67.29% to $900.0 million in 2023, then crashed by 72.47% to $247.8 million in 2024, then fell by 17.98% to $203.2 million in 2025.
  • Its last three reported values are $203.2 million in Q4 2025, $224.2 million for Q3 2025, and $231.6 million during Q2 2025.